secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clovis Oncology, Inc. (—)
CIK:        0001466301
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001193125-23-101292
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Clovis Oncology completes sale of FAP-2286 to Novartis amid Chapter 11
----------------------------------------------------------------------

- Sale of pipeline targeted radionuclide therapy program FAP-2286 closed April 14, 2023.
- Court approved the transaction on March 21, 2023; sale includes in-licensing agreement with 3B Pharmaceuticals.
- Company expects no payment to common stockholders given senior debt and contingent milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523101292/0001193125-23-101292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523101292/d458873d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-101292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer